Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.8735 EUR -0.8% Market Closed
Market Cap: 592.5m EUR
Have any thoughts about
Pharming Group NV?
Write Note

Operating Margin
Pharming Group NV

-5%
Current
2%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5%
=
Operating Profit
-14.3m
/
Revenue
285.7m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NL
Pharming Group NV
AEX:PHARM
592.7m EUR
-5%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
309B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.5B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country NL
Market Cap 592.7m EUR
Operating Margin
-5%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 309B USD
Operating Margin
28%
Country US
Market Cap 141B USD
Operating Margin
19%
Country US
Market Cap 116B USD
Operating Margin
38%
Country US
Market Cap 103.5B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Pharming Group NV
Glance View

Market Cap
592.7m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
1.1978 EUR
Undervaluation 27%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5%
=
Operating Profit
-14.3m
/
Revenue
285.7m
What is the Operating Margin of Pharming Group NV?

Based on Pharming Group NV's most recent financial statements, the company has Operating Margin of -5%.